News | June 06, 2022
Merck’s pembrolizumab demonstrates improvement in distant metastasis
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
The production suspension impacts commercial and clinical trial supply
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
